Papillary Adenocarcinoma — Trials

Papillary Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 48
Recruiting: 19
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 51–69 of 69 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00027820	Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	completed	Phase 1 / Phase 2	106	Fred Hutchinson Cancer CenterOTHER	3	Dec 20, 2019	clinicaltrials
NCT01010126	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	completed	Phase 2	252	National Cancer Institute (NCI)NIH	2	Jan 25, 2019